DAWN – Day One Biopharmaceuticals, Inc.
Float Short %
12.19
Margin Of Safety %
Put/Call OI Ratio
0.19
EPS Next Q Diff
EPS Last/This Y
0.05
EPS This/Next Y
0.32
Price
8.64
Target Price
22.25
Analyst Recom
1.22
Performance Q
16.6
Relative Volume
4.87
Beta
-1.26
Ticker: DAWN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | DAWN | 10.16 | 0.15 | 0.00 | 37517 |
| 2025-11-11 | DAWN | 10.35 | 0.11 | 1.77 | 49360 |
| 2025-11-12 | DAWN | 10.33 | 0.15 | 0.00 | 49008 |
| 2025-11-13 | DAWN | 8.84 | 0.15 | 0.17 | 49183 |
| 2025-11-14 | DAWN | 8.78 | 0.17 | 0.03 | 50140 |
| 2025-11-17 | DAWN | 8.84 | 0.15 | 0.00 | 55703 |
| 2025-11-18 | DAWN | 8.56 | 0.14 | 0.74 | 60296 |
| 2025-11-19 | DAWN | 8.4 | 0.14 | 0.78 | 60332 |
| 2025-11-20 | DAWN | 8.28 | 0.14 | 0.12 | 60377 |
| 2025-11-21 | DAWN | 8.51 | 0.15 | 0.21 | 61322 |
| 2025-11-24 | DAWN | 8.87 | 0.18 | 0.01 | 44959 |
| 2025-11-25 | DAWN | 9.43 | 0.15 | 0.45 | 54611 |
| 2025-11-26 | DAWN | 9.41 | 0.16 | 6.51 | 55763 |
| 2025-12-01 | DAWN | 8.77 | 0.17 | 0.76 | 56565 |
| 2025-12-02 | DAWN | 8.43 | 0.18 | 2.40 | 56680 |
| 2025-12-03 | DAWN | 8.31 | 0.18 | 0.10 | 57054 |
| 2025-12-04 | DAWN | 8.34 | 0.19 | 2.49 | 57028 |
| 2025-12-05 | DAWN | 7.91 | 0.18 | 0.57 | 57001 |
| 2025-12-08 | DAWN | 8.64 | 0.19 | 2.06 | 57138 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | DAWN | 10.16 | 53.4 | - | -1.17 |
| 2025-11-11 | DAWN | 10.36 | 53.4 | - | -0.99 |
| 2025-11-12 | DAWN | 10.34 | 53.4 | - | -0.96 |
| 2025-11-13 | DAWN | 8.85 | 53.4 | - | -0.96 |
| 2025-11-14 | DAWN | 8.79 | 66.1 | - | -0.96 |
| 2025-11-17 | DAWN | 8.84 | 66.1 | - | -0.96 |
| 2025-11-18 | DAWN | 8.56 | 66.1 | - | -0.97 |
| 2025-11-19 | DAWN | 8.41 | 66.1 | - | -0.97 |
| 2025-11-20 | DAWN | 8.28 | 66.1 | - | -0.97 |
| 2025-11-21 | DAWN | 8.51 | 68.1 | - | -0.97 |
| 2025-11-24 | DAWN | 8.88 | 68.1 | - | -0.97 |
| 2025-11-25 | DAWN | 9.43 | 68.1 | - | -0.97 |
| 2025-11-26 | DAWN | 9.42 | 68.1 | - | -0.97 |
| 2025-12-01 | DAWN | 8.77 | 68.1 | - | -0.97 |
| 2025-12-02 | DAWN | 8.43 | 68.1 | - | -0.97 |
| 2025-12-03 | DAWN | 8.31 | 68.1 | - | -0.97 |
| 2025-12-04 | DAWN | 8.34 | 68.1 | - | -0.97 |
| 2025-12-05 | DAWN | 7.92 | 68.1 | - | -0.97 |
| 2025-12-08 | DAWN | 8.64 | 68.1 | - | -0.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | DAWN | -0.20 | -5.43 | 13.50 |
| 2025-11-11 | DAWN | -0.20 | -5.43 | 13.50 |
| 2025-11-12 | DAWN | -0.20 | -5.43 | 12.17 |
| 2025-11-13 | DAWN | -0.20 | -5.43 | 12.17 |
| 2025-11-14 | DAWN | -0.20 | -5.43 | 12.17 |
| 2025-11-17 | DAWN | -0.20 | 1.13 | 12.16 |
| 2025-11-18 | DAWN | -0.20 | 1.13 | 12.16 |
| 2025-11-19 | DAWN | -0.29 | 1.13 | 12.16 |
| 2025-11-20 | DAWN | -0.20 | 1.13 | 12.16 |
| 2025-11-21 | DAWN | -0.20 | 1.13 | 12.16 |
| 2025-11-24 | DAWN | -0.20 | -0.52 | 12.33 |
| 2025-11-25 | DAWN | -0.19 | -0.52 | 12.33 |
| 2025-11-26 | DAWN | -0.19 | -0.52 | 12.20 |
| 2025-12-01 | DAWN | -0.19 | -0.58 | 12.20 |
| 2025-12-02 | DAWN | -0.19 | -0.58 | 12.20 |
| 2025-12-03 | DAWN | -0.19 | -0.58 | 12.20 |
| 2025-12-04 | DAWN | -0.19 | -0.58 | 12.20 |
| 2025-12-05 | DAWN | -0.19 | -0.58 | 12.19 |
| 2025-12-08 | DAWN | -0.19 | -0.58 | 12.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.2
Avg. EPS Est. Next Quarter
-0.19
Insider Transactions
-0.19
Institutional Transactions
-0.58
Beta
-1.26
Average Sales Estimate Current Quarter
44
Average Sales Estimate Next Quarter
50
Fair Value
Quality Score
38
Growth Score
28
Sentiment Score
1
Actual DrawDown %
69.9
Max Drawdown 5-Year %
Target Price
22.25
P/E
Forward P/E
PEG
P/S
6.64
P/B
1.97
P/Free Cash Flow
EPS
-1.49
Average EPS Est. Cur. Y
-0.97
EPS Next Y. (Est.)
-0.65
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-113.53
Relative Volume
4.87
Return on Equity vs Sector %
-60.5
Return on Equity vs Industry %
-45.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.21
EBIT Estimation
Day One Biopharmaceuticals, IncSector: Healthcare
Industry: Biotechnology
Employees: 184
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
stock quote shares DAWN – Day One Biopharmaceuticals, Inc. Stock Price stock today
news today DAWN – Day One Biopharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DAWN – Day One Biopharmaceuticals, Inc. yahoo finance google finance
stock history DAWN – Day One Biopharmaceuticals, Inc. invest stock market
stock prices DAWN premarket after hours
ticker DAWN fair value insiders trading